Advertisement

Immune Signatures Associated with the Cancer Bearing State

  • Rebecca J. Critchley-Thorne
  • Hongxiang Yu
  • Peter P. Lee
Chapter

Abstract

Dysfunction of the host immune system can be detected in many patients with different cancer types, and contributes to tumor escape and failure of therapies that aim to elicit or boost anti-tumor immunity. Yet, immune-mediated tumor rejection and long term cancer control have been documented in a minority of patients. A better understanding of immune dysfunction in the cancer bearing state and the immune mechanisms that lead to tumor rejection will enable design of novel therapeutic approaches to overcome cancer-induced immune dysfunction and augment effective anti-tumor immunity. This chapter discusses the signatures associated with immune dysfunction vs. immune-mediated rejection in cancer patients, and highlights the applications of such signatures in cancer diagnostic testing and as therapeutic opportunities.

Keywords

Immune dysfunction Anergy Tumor rejection Immunotherapy Immune biomarkers 

References

  1. Attia P, Phan GQ, Maker AV et al. (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 (25): 6043–53.PubMedCrossRefGoogle Scholar
  2. Barrier A, Roser F, Boelle PY et al. (2007) Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26 (18): 2642–8.PubMedCrossRefGoogle Scholar
  3. Bates GJ, Fox SB, Han C et al. (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24 (34): 5373–80.PubMedCrossRefGoogle Scholar
  4. Bauernhofer T, Kuss I, Henderson B et al. (2003a) Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 33 (1): 119–24.PubMedCrossRefGoogle Scholar
  5. Bauernhofer T, Kuss I, Friebe-Hoffmann U et al. (2003b) Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer. Br J Cancer 88 (8): 1301–9.PubMedCrossRefGoogle Scholar
  6. Beano A, Signorino E, Evangelista A et al. (2008) Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 6 (1): 25.PubMedCrossRefGoogle Scholar
  7. Botella-Estrada R, Escudero M, O’Connor JE et al. (2005) Cytokine production by peripheral lymphocytes in melanoma. Eur Cytokine Netw 16 (1): 47–55.PubMedGoogle Scholar
  8. Bronte V, Chappell DB, Apolloni E et al. (1999) Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162 (10): 5728–37.PubMedGoogle Scholar
  9. Brydak LB, Guzy J, Starzyk J et al. (2001) Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 9 (1): 65–8.PubMedCrossRefGoogle Scholar
  10. Budhu A, Forgues M, Ye QH et al. (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10 (2): 99–111.PubMedCrossRefGoogle Scholar
  11. Carpenter EL, Mick R, Rech AJ et al. (2009) Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 15 (13): 4277–87.PubMedCrossRefGoogle Scholar
  12. Castriconi R, Cantoni C, Della Chiesa M et al. (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 100 (7): 4120–5.PubMedCrossRefGoogle Scholar
  13. Cerundolo V, Silk JD, Masri SH et al. (2009) Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 9 (1): 28–38.PubMedCrossRefGoogle Scholar
  14. Chaput N, Louafi S, Bardier A et al. (2009) Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58 (4): 520–9.PubMedCrossRefGoogle Scholar
  15. Chen W, Jin W, Hardegen N et al. (2003) Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198 (12): 1875–86.PubMedCrossRefGoogle Scholar
  16. Chikamatsu K, Sakakura K, Whiteside TL et al. (2007) Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck 29 (2): 120–7.PubMedCrossRefGoogle Scholar
  17. Coronella JA, Spier C, Welch M et al. (2002) Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169 (4): 1829–36.PubMedGoogle Scholar
  18. Costello RT, Sivori S, Marcenaro E et al. (2002) Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99 (10): 3661–7.PubMedCrossRefGoogle Scholar
  19. Critchley-Thorne RJ, Yan N, Nacu S et al. (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4 (5): e176.PubMedCrossRefGoogle Scholar
  20. Critchley-Thorne RJ, Simons DL, Yan N et al. (2009a) Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A 106 (22): 9010–5.PubMedCrossRefGoogle Scholar
  21. Critchley-Thorne RJ, Miller SM, Taylor DL et al. (2009b) Applications of cellular systems biology in breast cancer patient stratification and diagnostics. Comb Chem High Throughput Screen 12 (9): 860–869.PubMedCrossRefGoogle Scholar
  22. Curiel TJ, Coukos G, Zou L et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (9): 942–9.PubMedCrossRefGoogle Scholar
  23. Curtsinger JM, Valenzuela JO, Agarwal P et al. (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174 (8): 4465–9.PubMedGoogle Scholar
  24. Della Bella S, Gennaro M, Vaccari M et al. (2003) Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89 (8): 1463–72.PubMedCrossRefGoogle Scholar
  25. Demir G, Klein HO, Mandel-Molinas N et al. (2007) Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol 7 (1): 113–6.PubMedCrossRefGoogle Scholar
  26. DeNardo DG, Johansson M and Coussens LM (2008) Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 27 (1): 11–8.PubMedCrossRefGoogle Scholar
  27. DiFronzo LA, Gupta RK, Essner R et al. (2002) Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 20 (15): 3242–8.PubMedGoogle Scholar
  28. Disis ML, Pupa SM, Gralow JR et al. (1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15 (11): 3363–7.PubMedGoogle Scholar
  29. Disis ML, Knutson KL, Schiffman K et al. (2000) Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62 (3): 245–52.PubMedCrossRefGoogle Scholar
  30. Dondi E, Roue G, Yuste VJ et al. (2004) A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response. J Immunol 173 (6): 3740–7.PubMedGoogle Scholar
  31. Duddy ME, Alter A and Bar-Or A (2004) Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 172 (6): 3422–7.PubMedGoogle Scholar
  32. Dunn GP, Bruce AT, Ikeda H et al. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (11): 991–8.PubMedCrossRefGoogle Scholar
  33. Dworacki G, Meidenbauer N, Kuss I et al. (2001) Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 7 (3 Suppl): 947–57s.PubMedGoogle Scholar
  34. Ebihara T, Sakai N and Koyama S (1991) Suppression by sorted CD8+CD11b-cells from T-cell growth factor-activated peripheral blood lymphocytes on cytolytic activity against tumour in patients with gastric carcinoma. Eur J Cancer 27 (12): 1654–7.PubMedCrossRefGoogle Scholar
  35. Elliott B, Scolyer RA, Suciu S et al. (2007) Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res 13 (13): 3825–30.PubMedCrossRefGoogle Scholar
  36. Ezernitchi AV, Vaknin I, Cohen-Daniel L et al. (2006) TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 177 (7): 4763–72.PubMedGoogle Scholar
  37. Fantini MC, Becker C, Monteleone G et al. (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172 (9): 5149–53.PubMedGoogle Scholar
  38. Fauriat C, Just-Landi S, Mallet F et al. (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109 (1): 323–30.PubMedCrossRefGoogle Scholar
  39. Ferrari S, Malugani F, Rovati B et al. (2005) Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. Oncol Rep 14 (1): 113–20.PubMedGoogle Scholar
  40. Finak G, Bertos N, Pepin F et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14 (5): 518–27.PubMedCrossRefGoogle Scholar
  41. Finke JH, Zea AH, Stanley J et al. (1993) Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53 (23): 5613–6.PubMedGoogle Scholar
  42. Frey AB (2006) Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest 116 (10): 2587–90.PubMedCrossRefGoogle Scholar
  43. Fridlender ZG, Sun J, Kim S et al. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16 (3): 183–94.PubMedCrossRefGoogle Scholar
  44. Gabrilovich D, Ishida T, Oyama T et al. (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (11): 4150–66.PubMedGoogle Scholar
  45. Gastman BR, Atarshi Y, Reichert TE et al. (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59 (20): 5356–64.PubMedGoogle Scholar
  46. Gennari R, Menard S, Fagnoni F et al. (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10 (17): 5650–5.PubMedCrossRefGoogle Scholar
  47. Gerosa F, Baldani-Guerra B, Nisii C et al. (2002) Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195 (3): 327–33.PubMedCrossRefGoogle Scholar
  48. Ghebeh H, Mohammed S, Al-Omair A et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8 (3): 190–8.PubMedCrossRefGoogle Scholar
  49. Ghiringhelli F, Menard C, Terme M et al. (2005a) CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202 (8): 1075–85.PubMedCrossRefGoogle Scholar
  50. Ghiringhelli F, Puig PE, Roux S et al. (2005b) Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 202 (7): 919–29.PubMedCrossRefGoogle Scholar
  51. Gogas H, Ioannovich J, Dafni U et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 (7): 709–18.PubMedCrossRefGoogle Scholar
  52. Groh V, Wu J, Yee C et al. (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (6908): 734–8.PubMedCrossRefGoogle Scholar
  53. Gruber IV, El Yousfi S, Durr-Storzer S et al. (2008) Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res 28 (2A): 779–84.PubMedGoogle Scholar
  54. Hamanishi J, Mandai M, Iwasaki M et al. (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104 (9): 3360–5.PubMedCrossRefGoogle Scholar
  55. Hoffmann TK, Dworacki G, Tsukihiro T et al. (2002a) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8 (8): 2553–62.PubMedGoogle Scholar
  56. Hoffmann TK, Muller-Berghaus J, Ferris RL et al. (2002b) Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8 (6): 1787–93.PubMedGoogle Scholar
  57. Hu Z, Fan C, Oh DS et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.PubMedCrossRefGoogle Scholar
  58. Huang B, Pan PY, Li Q et al. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66 (2): 1123–31.PubMedCrossRefGoogle Scholar
  59. Ichihara F, Kono K, Takahashi A et al. (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9 (12): 4404–8.PubMedGoogle Scholar
  60. Jarnicki AG, Lysaght J, Todryk S et al. (2006) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177 (2): 896–904.PubMedGoogle Scholar
  61. Kim HK, Song KS, Park YS et al. (2003) Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 39 (2): 184–91.PubMedCrossRefGoogle Scholar
  62. Kim JW, Wieckowski E, Taylor DD et al. (2005) Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11 (3): 1010–20.PubMedGoogle Scholar
  63. Ko K, Yamazaki S, Nakamura K et al. (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202 (7): 885–91.PubMedCrossRefGoogle Scholar
  64. Ko JS, Zea AH, Rini BI et al. (2009a) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15 (6): 2148–57.PubMedCrossRefGoogle Scholar
  65. Ko JS, Bukowski RM and Fincke JH (2009b) Myeloid-derived suppressor cells: a novel therapeutic target. Curr Oncol Rep 11 (2): 87–93.PubMedCrossRefGoogle Scholar
  66. Kohrt HE, Nouri N, Nowels K et al. (2005) Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2 (9): e284.PubMedCrossRefGoogle Scholar
  67. Kolumam GA, Thomas S, Thompson LJ et al. (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202 (5): 637–50.PubMedCrossRefGoogle Scholar
  68. Kono K, Ressing ME, Brandt RM et al. (1996) Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2 (11): 1825–8.PubMedGoogle Scholar
  69. Kuss I, Rabinowich H, Gooding W et al. (2002) Expression of zeta in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biother Radiopharm 17 (6): 631–40.PubMedCrossRefGoogle Scholar
  70. Ladanyi A, Kiss J, Somlai B et al. (2007) Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56 (9): 1459–69.PubMedCrossRefGoogle Scholar
  71. Le Bon A, Thompson C, Kamphuis E et al. (2006) Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 176 (4): 2074–8.PubMedGoogle Scholar
  72. Le Maux Chansac B, Moretta A, Vergnon I et al. (2005) NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 175 (9): 5790–8.Google Scholar
  73. Lee PP, Zeng D, McCaulay AE et al. (1997) T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood 90 (4): 1611–7.PubMedGoogle Scholar
  74. Lee PP, Yee C, Savage PA et al. (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5 (6): 677–85.PubMedCrossRefGoogle Scholar
  75. Lee JC, Lee KM, Kim DW et al. (2004) Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172 (12): 7335–40.PubMedGoogle Scholar
  76. Li H, Han Y, Guo Q et al. (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182 (1): 240–9.PubMedGoogle Scholar
  77. Lin EY, Gouon-Evans V, Nguyen AV et al. (2002) The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 7 (2): 147–62.PubMedCrossRefGoogle Scholar
  78. Liyanage UK, Moore TT, Joo HG et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169 (5): 2756–61.PubMedGoogle Scholar
  79. Madjd Z, Spendlove I, Moss R et al. (2007) Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun 7: 17.PubMedGoogle Scholar
  80. Miyahara Y, Odunsi K, Chen W et al. (2008) Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 105 (40): 15505–10.PubMedCrossRefGoogle Scholar
  81. Molling JW, Kolgen W, van der Vliet HJ et al. (2005) Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116 (1): 87–93.PubMedCrossRefGoogle Scholar
  82. Molling JW, Langius JA, Langendijk JA et al. (2007) Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25 (7): 862–8.PubMedCrossRefGoogle Scholar
  83. Mortarini R, Vegetti C, Molla A et al. (2009) Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res 15 (12): 4085–94.PubMedCrossRefGoogle Scholar
  84. Moschos SJ, Mandic M, Kirkwood JM et al. (2008) Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol 127 (2): 123–9.PubMedCrossRefGoogle Scholar
  85. Mosmann T (2000) Complexity or coherence? Cytokine secretion by B cells. Nat Immunol 1 (6): 465–6.PubMedCrossRefGoogle Scholar
  86. Muranski P, Boni A, Antony PA et al. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112 (2): 362–73.PubMedCrossRefGoogle Scholar
  87. Nakamura H, Saji H, Ogata A et al. (2002) Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 37 (2): 161–9.PubMedCrossRefGoogle Scholar
  88. Nakano M, Kawanishi Y, Kuriyama Y et al. (2000) Spontaneous reduction of leukemic lymphoma cells possibly by anti-tumor antibody-mediated phagocytosis; a kappa lambda-dual-positive B cell lymphoma. Leukemia 14 (2): 278–84.PubMedCrossRefGoogle Scholar
  89. Nemunaitis J, Fong T, Shabe P et al. (2001) Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 19 (3): 239–47.PubMedCrossRefGoogle Scholar
  90. Nordlund JJ, Kirkwood JM, Forget BM et al. (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9 (5): 689–96.PubMedCrossRefGoogle Scholar
  91. Norian LA, Rodriguez PC, O’Mara LA et al. (2009) Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res 69 (7): 3086–94.PubMedCrossRefGoogle Scholar
  92. Ochoa AC, Zea AH, Hernandez C et al. (2007) Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13 (2 Pt 2): 721–26s.PubMedCrossRefGoogle Scholar
  93. Okita R, Saeki T, Takashima S et al. (2005) CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 14 (5): 1269–73.PubMedGoogle Scholar
  94. Osaki T, Saito H, Yoshikawa T et al. (2007) Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res 13 (2 Pt 1): 382–7.PubMedCrossRefGoogle Scholar
  95. Ostrand-Rosenberg S (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18 (1): 11–8.PubMedCrossRefGoogle Scholar
  96. Park SJ, Nakagawa T, Kitamura H et al. (2004) IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173 (6): 3844–54.PubMedGoogle Scholar
  97. Pavoni E, Monteriu G, Santapaola D et al. (2007) Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. BMC Biotechnol 7 (1): 70.PubMedCrossRefGoogle Scholar
  98. Phan GQ, Wang E and Marincola FM (2001) T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin Biol Ther 1 (3): 511–23.PubMedCrossRefGoogle Scholar
  99. Pinzon-Charry A, Ho CS, Laherty R et al. (2005) A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia 7 (12): 1112–22.PubMedCrossRefGoogle Scholar
  100. Pinzon-Charry A, Maxwell T, McGuckin MA et al. (2006) Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res 8 (1): R5.PubMedCrossRefGoogle Scholar
  101. Pinzon-Charry A, Ho CS, Maxwell T et al. (2007) Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer 97 (9): 1251–9.PubMedCrossRefGoogle Scholar
  102. Reichert TE, Day R, Wagner EM et al. (1998) Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58 (23): 5344–7.PubMedGoogle Scholar
  103. Reichert TE, Strauss L, Wagner EM et al. (2002) Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8 (10): 3137–45.PubMedGoogle Scholar
  104. Rodriguez PC, Quiceno DG, Zabaleta J et al. (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64 (16): 5839–49.PubMedCrossRefGoogle Scholar
  105. Rodriguez-Pinto D and Moreno J (2005) B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur J Immunol 35 (4): 1097–105.PubMedCrossRefGoogle Scholar
  106. Rody A, Holtrich U, Pusztai L et al. (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11 (2): R15.PubMedCrossRefGoogle Scholar
  107. Roepman P, Jassem J, Smit EF et al. (2009) An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 15 (1): 284–90.PubMedCrossRefGoogle Scholar
  108. Ross MB, Buzdar AU, Hortobagyi GN et al. (1982) Spontaneous regression of breast carcinoma: follow-up report and literature review. J Surg Oncol 19 (1): 22–4.PubMedCrossRefGoogle Scholar
  109. Sabbioni ME, Siegrist HP, Bacchi M et al. (2000) Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast Cancer Res Treat 59 (3): 279–87.PubMedCrossRefGoogle Scholar
  110. Sakakura K, Chikamatsu K, Takahashi K et al. (2006) Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 55 (2): 151–9.PubMedCrossRefGoogle Scholar
  111. Santin AD, Bellone S, Ravaggi A et al. (2001) Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 108 (8): 804–8.PubMedGoogle Scholar
  112. Schiffman K, Rinn K and Disis ML (2002) Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients. Breast Cancer Res Treat 74 (1): 17–23.PubMedCrossRefGoogle Scholar
  113. Seike M, Yanaihara N, Bowman ED et al. (2007) Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 99 (16): 1257–69.PubMedCrossRefGoogle Scholar
  114. Seo N, Hayakawa S, Takigawa M et al. (2001) Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103 (4): 449–57.PubMedCrossRefGoogle Scholar
  115. Sfanos KS, Bruno TC, Maris CH et al. (2008) Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14 (11): 3254–61.PubMedCrossRefGoogle Scholar
  116. Showe MK, Vachani A, Kossenkov AV et al. (2009) Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 69 (24): 9202–10.PubMedCrossRefGoogle Scholar
  117. Sica A, Larghi P, Mancino A et al. (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18 (5): 349–55.PubMedCrossRefGoogle Scholar
  118. Staveley-O’Carroll K, Sotomayor E, Montgomery J et al. (1998) Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 95 (3): 1178–83.PubMedCrossRefGoogle Scholar
  119. Steinbrink K, Graulich E, Kubsch S et al. (2002) CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99 (7): 2468–76.PubMedCrossRefGoogle Scholar
  120. Tahir SM, Cheng O, Shaulov A et al. (2001) Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167 (7): 4046–50.PubMedGoogle Scholar
  121. Taylor DD, Bender DP, Gercel-Taylor C et al. (2001) Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer 84 (12): 1624–9.PubMedCrossRefGoogle Scholar
  122. Taylor DD, Gercel-Taylor C, Lyons KS et al. (2003) T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 9 (14): 5113–9.PubMedGoogle Scholar
  123. Tazzyman S, Lewis CE and Murdoch C (2009) Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 90 (3): 222–31.PubMedCrossRefGoogle Scholar
  124. Teschendorff AE, Miremadi A, Pinder SE et al. (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8 (8): R157.PubMedCrossRefGoogle Scholar
  125. Tsutsui S, Yasuda K, Suzuki K et al. (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14 (2): 425–31.PubMedGoogle Scholar
  126. Ueda R, Low KL, Zhu X et al. (2007) Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med 5: 68.PubMedCrossRefGoogle Scholar
  127. Vallisa D, Cavanna L, Berte R et al. (1995) Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 93 (1): 31–5.PubMedCrossRefGoogle Scholar
  128. Varchetta S, Gibelli N, Oliviero B et al. (2007) Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67 (24): 11991–9.PubMedCrossRefGoogle Scholar
  129. Varker KA, Terrell CE, Welt M et al. (2007) Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J Surg Res 139 (1): 36–44.PubMedCrossRefGoogle Scholar
  130. von Bergwelt-Baildon MS, Popov A, Saric T et al. (2006) CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108 (1): 228–37.CrossRefGoogle Scholar
  131. Wang E, Miller LD, Ohnmacht GA et al. (2002) Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62 (13): 3581–6.PubMedGoogle Scholar
  132. Wang E, Panelli MC, Zavaglia K et al. (2004) Melanoma-restricted genes. J Transl Med 2 (1): 34.PubMedCrossRefGoogle Scholar
  133. Wei S, Kryczek I, Zou L et al. (2005) Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 65 (12): 5020–6.PubMedCrossRefGoogle Scholar
  134. Whiteside TL (2004) Down-regulation of zeta-chain expression in T cells: a biomarker of ­prognosis in cancer? Cancer Immunol Immunother 53 (10): 865–78.PubMedCrossRefGoogle Scholar
  135. Yacyshyn MB, Poppema S, Berg A et al. (1995) CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: ­correlations with survival following active specific immunotherapy. Int J Cancer 61 (4): 470–4.PubMedCrossRefGoogle Scholar
  136. Yamshchikov G, Thompson L, Ross WG et al. (2001) Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin Cancer Res 7 (3 Suppl): 909–16s.PubMedGoogle Scholar
  137. Yamshchikov GV, Mullins DW, Chang CC et al. (2005) Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 174 (11): 6863–71.PubMedGoogle Scholar
  138. Yuen MF, Hughes RD, Heneghan MA et al. (2001) Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver-infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma. Cancer 92 (8): 2136–41.PubMedCrossRefGoogle Scholar
  139. Zea AH, Curti BD, Longo DL et al. (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1 (11): 1327–35.PubMedGoogle Scholar
  140. Zippelius A, Batard P, Rubio-Godoy V et al. (2004) Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64 (8): 2865–73.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Rebecca J. Critchley-Thorne
  • Hongxiang Yu
  • Peter P. Lee
    • 1
  1. 1.Division of Hematology, Department of MedicineStanford UniversityStanfordUSA

Personalised recommendations